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ABSTRACT
Pyroglutamic acid (also known as 5-oxoproline) is an organic acid intermediate of the 
gamma-glutamyl cycle. Accumulation of pyroglutamic acid is a rare cause of high anion 
gap metabolic acidosis. In the pediatric population, the congenital form of pyroglutamic 
acidemia has been extensively described. However, there are scarce reports of the 
acquired form of this condition in children. The urine test for organic acids confirms 
the diagnosis of pyroglutamic acidemia. We report the case of a 16-month-old girl 
who developed transient 5-oxoprolinemia associated with malnutrition and the use of 
acetaminophen and ampicillin for the treatment of acute otitis media and abdominal 
pain. The patient received 21-hour course of n-acetylcysteine with improvement of 
metabolic acidosis. This report highligts the need of considering pyroglutamic acidemia 
in the differencial diagnosis for high anion gap metabolic acidosis in pediatric patients 
with malnutrition and other risk factors.
Keywords: Glutathione synthetase deficiency; 5-oxoprolinemia; pyroglutamic acidemia; 
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Pyroglutamic acid (PGA) or 5-oxoproline is an organic acid intermediate 
of the gamma-glutamyl cycle. PGA accumulation is a rare cause of metabolic 
acidemia1-3. In adults, the presence of certain underlying medical conditions 
and use of several drugs have been implicated in the development of transient 
pyroglutamic acidemia1-3. In the pediatric population, the congenital form of 
pyroglutamic acidemia has been described,4 as well as some scarce reports 
of acquired acidemia5,6. Urine tests for organic acids confirm the diagnosis 
of this condition3. We present a pediatric case of a patient who developed 
transient 5-oxoprolinemia following malnutrition and use of acetaminophen 
and ampicillin. We also briefly discuss the biochemistry related to PGA 
accumulation and risk factors linked to this pathologic process.
CASE REPORT
A previously healthy African-American 16-month-old girl was admitted to 
hospital because of non-intentional esophageal injury by caustic soda. She was 
the only child of nonconsanguineous parents, without known genetic diseases 
in the family. Upper gastrointestinal tract endoscopy revealed constriction 
10 cm beyond superior dental arch, with enantema, friability, and exsudate 
bridges. Upper gastrointestinal X-ray series showed severe constriction of the 
middle and inferior esophagus. Stomach could not be properly evaluated due 
to aspiration of barium during exam; hence, it was considered as damaged. 
Therefore, the patient underwent jejunostomy for feeding. Afterwards, she was 
followed in an outpatient clinic and had significant weight loss (from 10 kg, 
z-score –0.19, before the injury to 7.18 kg, z-score –3.49, after three months) 
and was admitted for nutritional recovery. Maltodextrin was introduced to her 
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diet and the patient improved weight gain (10 g/kg/day) 
and was discharged 15 days later (weight: 8.27 kg).
On a follow-up outpatient visit, one week later, the 
patient presented again with significant weight loss 
(6.99 kg) and had to be readmitted. Upon arrival she 
was asymptomatic but had signs of mild dehydration. 
Laboratory tests showed hypoalbuminemia (2.4 g/dL), 
normochromic-normocytic anemia (Hb 10.2 g/dL), 
and high anion gap metabolic acidemia (pH 7.22, 
PCO2 23.3, HCO3 9.4, BE –16, anion gap 17.6), 
as well as electrolyte disturbances (hyponatremia, 
hypomagnesemia and hypokalemia). Serum sodium 
was 132 mEq/L and serum chloride was 105 mEq/L 
at this time.
She was initially managed with fluid, magnesium, 
potassium and sodium bicarbonate replacement, 
with poor response regarding acidemia correction 
(pH 7.23, PCO2 20.2, HCO3 8.2, BE –17.8). Workup 
for high anion gap acidemia revealed elevated plasma 
lactate (6.39 mmol/L) and a urinary anion gap of 
–23. At first, refeeding syndrome was suspected, but 
metabolic acidosis persisted for the next days (nadir 
pH and HCO3 = 7.08 and 4, respectively). Because 
the patient had severe malnutrition and duodenal 
bypass secondary to jejunostomy feeding, intravenous 
thiamine was started. However, treatment failed. 
Bacterial overgrowth was suspected due to abdominal 
distension and persistent diarrhea. The patient was 
treated with a 5-day course of metronidazol every 
15 days. Empirical treatment with biotin, cobalamin 
and l-carnitine was also established without response. 
During hospital stay, the patient received amoxicillin 
and ampicilin (acute otitis media) and acetaminophen 
for several days due to fever (acute otitis media) and 
abdominal pain (abdominal distension due to bacterial 
overgrowth). Amoxicilin, ampicilin and acetaminophen 
were all given prior to the development of high anion 
gap acidemia. She developed periorbital, hands and 
feet edema. Echocardiogram was normal.
Since the patient had persistently poor weight 
gain despite adequate diet and signs of bacterial 
overgrowth, she was investigated for the presence 
of short bowel syndrome. It was hypothesized that 
she could have an improper position of the distal 
extremity of jejunal tube or a compromised small 
bowel absorptive surface secondary to acid injury. 
A radiography performed after injection of barium 
through the jejunostomy tube showed that its extremity 
was 4 cm far from the ileocecal valve, compatible 
with a jejuno-ileal fistula. Parenteral nutrition was 
then initiated and the patient started gaining weight 
(8.9 kg–10 g/kg/day) and improved her albumin 
levels (4.1 g/dL).
Since severe metabolic acidemia persisted and 
lactate returned to normal levels, pyroglutamic 
acidemia was suspected. At this time, serum 
sodium was 133 mEq/L and serum chloride was 
108 mEq/L. PGA was moderately elevated in urine 
sample. The patient received a 21-hour course of 
n-acetylcysteine with improvement of metabolic 
acidemia (pH 7.38, PCO2 39.1, HCO3 23, EB -1.3, 
anion gap 7) (figure 1). PGA in the urine was within 
normal range after treatment. The patient had 
hyperglycemia during n-acetylcysteine infusion with 
dextrose 5%. She was concomitantly receiving total 
parenteral nutrition with a 6.5 mg/kg/min glucose 
infusion rate.
The patient progressed without new episodes of 
acidemia. All medications implicated in pyroglutamic 
acidemia were avoided. The patient underwent 
esophagectomy and gastric pull-up. Two thirds of 
esophagus were removed. During the procedure, the 
hypothesis of jejunal fistula was confirmed. At the 
reminiscent proximal esophagus, there was a severe 
stricture that was treated with dilations. The patient 
will be fed via nasoenteral tube until the dilations are 
completed and dysphagia is currently being treated 
by a speech therapist.
DISCUSSION
Transient severe anion gap metabolic acidosis 
due to 5-oxoprolinemia, also known as pyroglutamic 
acidemia, is a rare clinical condition caused by 
glutathione deficiency1-3. Although this condition is 
supposed to be encountered at any age, this is the 
third pediatric case reported5,6.
PGA is produced in the gamma-glutamyl cycle, 
responsible for generating glutathione and membrane 
transport of amino acids into cytosol. PGA is primarily 
metabolized to glutamate by enzyme 5-oxoprolinase 
and is eliminated by the renal system. In this pathway, 
normal glutathione stores are required for feedback 
suppression of the enzyme gamma-glutamyl cysteine 
synthetase, which controls the activity of the cycle1,7,8 
Figure 1: Effect of n-acetylcysteine administration on pH. 
Patient’s pH increased after administration of intravenous 
n-acetylcysteine (arrow).
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(figure 2). High anion gap metabolic acidosis (HAGMA) 
caused by PGA results from lack of glutathione and 
disruption of the gamma-glutamyl cycle, once large 
amounts of gamma-glutamyl cysteine are metabolized 
by gamma-glutamyl cyclotransferase to produce 
PGA directly1,7.
It is well established in adults that the therapeutic 
use of acetaminophen combined with risk factors 
such as malnutrition, severe sepsis, artificial feeding, 
hepatic disease, diabetes, pregnancy, renal failure, 
and use of penicillin and vigabatrin is a cause of 
transient 5-oxoprolinemia1-3,8. Acetaminophen and 
vigabatrin deplete glutathione stores, leading to loss 
of feedback inhibition and increased production of 
5-oxoproline from its precursor gamma-glutamyl 
cysteine. Without the aforementioned risk factors, 
acetaminophen alone is an unlikely cause of 
PGA-induced anion gap acidosis. Female gender 
is another likely risk factor2,8.
Our patient had risk factors that lead to PGA 
accumulation. She was severely malnourished and 
used acetaminophen and ampicillin for several days. 
The increased levels of lactic acid contributed to 
her acidemia, but the levels were not sufficient to 
explain the severity of acidosis. Metronidazole was 
also given prior to the development of acidemia, 
which may have contributed to the development 
of the disease. However, we were not able to find 
any article describing an association between the 
use of metronidazole and pyroglutamic acidemia. 
Therefore, we believe that ampicillin/amoxicillin and 
acetaminophen were the drugs most likely involved 
in the pathogenesis of the disease.
Some polymorphisms for the glutathione synthetase 
enzyme have been described, especially in cases 
of HAGMA with 5-oxoprolinemia that occur later in 
life under particular metabolic stress, suggesting a 
previously unrecognized genetic defect. Aside from the 
polymorphism, there also exists acquired glutathione 
synthetase deficiency because the enzyme may not 
perform equally well across the person’s life span1.
Hereditary 5-oxoprolinemia is a result of autosomal 
recessive deficiencies caused by hereditary error in 
one of the enzymes involved in the gamma-glutamyl 
cycle, as glutathione synthetase and 5-oxoprolinase 
deficiency3,8. These rare metabolic disorders usually 
present in neonates with hemolytic anemia and 
neurological defects1,7. Therefore, it is very unlikely 
that the girl described in our case report presented 
the hereditary form of the disease.
Concerning treatment, n-acetylcysteine use is a 
plausible option based on the glutathione deficiency 
of the disorder, as it provides the cysteine necessary 
for glutathione syntesis1. There are no strong evidence 
supporting its use, but it was shown to be effective 
in several cases reports9-12.
Previous reports of aquired pyroglutamic acidemia 
in pediatric patients also found that this condition 
was associated with the use of acetaminophen5,6. 
Arboledas et al. described a 16 month-old patient with 
hemolytic uremic syndrome that developed HAGMA 
requiring hemodialysis5, while Pitt et al. described one 
case associated with pneumonia in a 5 year-old child 
and one case of septic shock in a 1 year-old6. Only 
the latter patient was treated with n-acetylcysteine6. 
Our patient had malnutrition as a main risk factor 
for the development of the disease. No other case 
reports in children described malnutrition associated 
with acquired pyroglutamic acidemia. 
Figure 2: Gamma-glutamyl cycle.
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CONCLUSION
This report highlights the importance of considering 
PGA accumulation in the context of profound high 
anion gap metabolic acidemia in pediatrics patients 
with known risk factors for this condition, such as 
malnutrition, which can be easily and promptly 
corrected with appropriate treatment.
PGA: pyroglutamic acid
HAGMA: high anion gap metabolic acidosis
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